Table S1 – Concentrations of compounds used for latency reversal studies

Compound	Chemical Class	Optimal Dose (μM)*	Observed GFP Expression in Primary Model (%)**
PMA	Phorbol Ester	50ng/mL	***
Ionomycin	Calcium Ionophore	1uM	***
Bryostatin	PKC Agonist	0.01	***
Panobinostat	HDAC Inhib	10	***
Romidepsin	HDAC Inhib	30	***
5-Azacytidine	DNMT Inhib	1	***
Disulfiram	Disulfide Dimer	0.40	50
HBB2(41)	Michael Reaction Acceptor	3.0	80
Shikonin(37)	Quinone	0.50	93
TBE-31(40)	Triterpenoid	1.0	76.10
Bortezomib	Protease Inhibitor	0.02	94.54

* - The optimal dose was obtained through dose-response curves in primary model cells. This represents the concentration with the highest GFP expression where >75% of cells are still viable by flow cytometry.

** - Primary model cells were treated with the stated concentration for 18 hours and then assessed for GFP expression by flow cytometry.

*** - Dose response was not performed as concentrations were taken from literature

Table S2 – Patient Characteristics

Race	Estimated Date of Infection	Date of Suppressive ART	Peak Reported Viral Load (Copies mL^{-1})	ART Regimen
Black/AA	1986	Dec-10	Unknown	abacavir-dolutegravir-lamivudine
Black/AA	1992	10/10/2008	Unknown	Dolutegravir/emtricitabine, rilpivirine, tenofovir alafenamide/Darunavir/ritonavir
Black/AA	Prior to 1995	1/7/2008	7160	emtricitabine-rilpivirine-tenofovir alafenamide/dolutegravir
Black/AA	1990	6/2/2009	25512	maraviroc/darunavir/raltegravir/ritonavir
Black/AA	Oct-94	1/22/2009	507612	elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide
Black/AA	Sep-95	3/14/2005	Unknown	BIC/TAF/FTC
Black/AA	1989	8/15/2012	248663	etravirine/maraviroc/raltegravir
Black/AA	1990	2/22/2012	548000	darunavir/cobicistat and dolutegravir
Black/AA	2007	5/10/2010	151114	emtricitabine and tenofovir alafenamide/dolutegravir
Black/AA	May-93	6/18/2015	175,052	darunavir/cobicistat; dolutegravir-rilpivirine
Black/AA	2002	6/2/2014	46462	efavirenz-emtricitabine-tenofovir disoproxi
Black/AA	Dec-04	4/1/2010	48368	atazanavir and cobicistat; emtricitabine and tenofovir alafenamide
Black/AA			Unknown	Elvitegravir/cobicistat/emtricitabine/tenofovir
Black/AA			Unknown	elvitegravir, cobicistat, emtricitabine, tenofovir
Black/AA			Unknown	Abacavir/dolutegravir/lamivudine

Table S3 – Primers and Probes Used

VQA	FWD	CAGATGCTGCATATAAGCAGCTG
	PRO	CCTGTACTGGGTCTCTCTGG
	REV	TTTTTTTTTTTTTTTTTTTTTTTTTGAAGCAC
ChIP LTR	FWD	CATCCGGAGTACTTCAAGAACTG
	PRO	TTGCTACAAGGGACTTTCCGCTGG
	REV	TGCTTATATGCAGGATCTGAGG
ChIP HSP70	FWD	TCTGATTGGTCCAAGGAAGGCT
	PRO	ATATTCCCGACCTGGCAGCCTCAT
	REV	CCCTTCTGAGCCAATCACCGA
ChIP Env	FWD	AGTGGTGCAGAGAGAAAAAAGAGC
	PRO	CCTTGGGTTCTTGGGA
	REV	GTCTGGCCTGTACCGTCAGC
ddPCR Read-Through	FWD	GCCCTCAGATGCTRCATATAA
	PRO	TGCCTGTACTGGGTCTCTCTGGTTAG
	REV	AGAGTCACACAACAGACGG
ddPCR TAR/Promoter Prox	FWD	GTCTCTCTGGTTAGACCAG
	PRO	AGCCTGGGAGCTC
	REV	TGGGTTCCCTAGYTAGCC
ddPCR Long LTR	FWD	GCCTCAATAAAGCTTGCCTTGA
	PRO	CCAGAGTCACACAACAGACGGGCACA
	REV	GGGCGCCACTGCTAGAGA
ddPCR MS Tat/Rev	FWD	CTTAGGCATCTCCTATGGCAGGAA
	PRO	ACCCGACAGGCC
	REV	GGATCTGTCTCTGTCTCTCTCTCCACC
ddPCR PolyA	FWD	GCCCTCAGATGCTRCATATAA
	PRO	TGCCTGTACTGGGTCTCTCTGGTTAG
	REV	TTTTTTTTTTTTTTTTTTTTTTTTTTTGAAG

Table S4 – ChIP ddPCR Assay Cycling Conditions

ddPCR Components	2x BioRad ddPCR Mastermix for Probes (no dUTP)		(per assay volume)
	Forward Primer		600nM
	Reverse Primer		600nM
	Fluorescent Probe		200nM
	Eluted DNA from ChIP		4µL
Cycling Conditins	95C		10 Minutes
	50 Cycles	95C	30 Seconds
		56C	2 Minutes
	98C		10 Minutes

Figure S1


A
B
C
D
%GFP
% Viability
100
80
60
40
20
0
-1.5
-1.0
-0.5
0.0
0.5
1.0
Log [Shikonin] uM
Log [Cycloshikonin] uM
Log [TP-225] uM
Log [TBE-31] uM

Figure S2


A
Patient A
Patient B
Patient C
Count
CycT1 (FITC)
PMA/I Isotype Control
PMA/I
PMA/I + KRIBB11
B
Patient A
LRA
Antibody
DMSO Isotype
PMA/I Isotype
DMSO α-CycT1
PANO α-CycT1
P/B α-CycT1
BORT α-CycT1
AZA α-CycT1
PMA/I α-CycT1
BRYO α-CycT1
C
Patient
LRA
Antibody
A DMSO Isotype
B DMSO Isotype
C DMSO Isotype
J-Lat 6.3 DMSO Isotype
A DMSO α-CycT1
B DMSO α-CycT1
C DMSO α-CycT1
J-Lat 6.3 DMSO α-CycT1